Pfizer Inc. (NYSE: PFE) Gets Breakthrough Therapy Designation For RSVpreF

The U.S Food and Drug Administration (FDA) has given Pfizer Inc. (NYSE: PFE) the Breakthrough Designation for RSVpreF, its vaccine for respiratory syncytial virus (RSV). The vaccine is for people aged 60 and above. This move comes after Pfizer conducted a Phase IIa clinical trial that looked into the efficacy, immunogenicity, and safety of the compound.

Pfizer announces positive results for etrasimod

The company has also announced good topline results for etrasimod after it conducted a Phase III trial. This compound could potentially treat moderate to severe ulcerative colitis. The researchers found that the respondents responded well to the drug, which seems to have a better effect than the placebo.

The team had gathered 354 patients with ulcerative colitis that had failed treatments or showed an allergic reaction to one of the typical therapies. They gave them a 2mg dose of etrasimod once every day.

Pfizer recalls some drugs for nitrosamine contamination

Pfizer is also recalling some of its medication due to contamination by nitrosamines. This is not the first time the company has recalled medication for this reason. Among the drugs the company is recalling are six Accuretic tablets and others that it distributed through Greenstone.

Nitrosamines are dangerous for their cancer-causing capabilities. Fortunately, the amount in the tablets isn’t enough to cause cancer. Moreover, the compound could only cause disease after a prolonged period and if taken in large doses. While Pfizer has confirmed that the nitrosamine levels in their pills aren’t dangerous, the company has still chosen to recall them.

Darnista, which is in Kyiv, is working hard despite the war to develop drugs badly needed by the Ukrainian population. The company is taking an even more significant challenge and manufacturing a version of Paxlovid, an oral COVID-19 vaccine Pfizer made.

Albert Bourla, the CEO and Chairman of Pfizer, could have made his mark on the world as one fi the most interesting people. After the COVID-19 pandemic began in 2020, Bourla has managed to lead the company to manufacture one of the best COVID-19 vaccines, thus saving the lives of millions.

Pfizer and Moderna Inc (NASDAQ: MRNA) are the first company to develop vaccines, with Pfizer doing it in nine months. This was ground-breaking as vaccines usually take years to create.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@wallstreetpr.com) or his Google+ page (https://plus.google.com/u/0/116608759701551457422).

Recent Stories

SignUp Now For Our Featured Newsletter